FGP
HAE icon

Freestone Grove Partners’s Haemonetics HAE Stock Holding History

Freestone Grove Partners’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$506K Buy
+8,972
New +$584K ﹤0.01% 595
2025
Q4 		– Sell
-30,260
Closed -$1.47M – 810
2025
Q3 		$1.47M Buy
+30,260
New +$1.87M 0.01% 398

Other funds holding HAE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
RRAM
River Road Asset Management Louisville, Kentucky $8.99B AUM 12.83% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Freestone Grove Partners's HAE Position: Q1 2026 in Review

Freestone Grove Partners opened a new position in Haemonetics (HAE) in Q1 2026: 8,972 shares worth $506K. The stake represents ﹤0.01% of the portfolio and ranks #595 among its holdings. This is a return to the name: Freestone Grove Partners previously reported a position in HAE as recently as Q3 2025.

Freestone Grove Partners first reported a position in HAE in Q3 2025 and has held it in 2 quarters since. The position peaked at $1.47M in Q3 2025. 324 funds tracked by Wall St. Rank hold HAE as of Q1 2026.

  • Freestone Grove Partners held 8,972 shares of Haemonetics worth $506K as of Q1 2026.
  • Haemonetics was a new Freestone Grove Partners position in Q1 2026.
  • Haemonetics made up ﹤0.01% of Freestone Grove Partners's portfolio in Q1 2026, its #595 holding.
  • Freestone Grove Partners first reported a position in Haemonetics in Q3 2025 and has held it in 2 quarters since.
  • Freestone Grove Partners's Haemonetics position peaked at $1.47M in Q3 2025.
  • 324 funds tracked by Wall St. Rank held Haemonetics as of Q1 2026.

Based on Freestone Grove Partners's 13F filing for Q1 2026, filed 15 May 2026.